A comparison of efficacy and safety of an ezetimibe/simvastatin combination compared with other intensified lipid-lowering treatment strategies in diabetic patients with symptomatic cardiovascular disease

Diabetes and Vascular Disease Research

Volumn 10, Issue 3, 2013, Pages 277-286

  Rosen, Jeffrey B ^a   Jimenez, Jose G ^b   Pirags, Valdis ^c   Vides, Hella ^d   Hanson, Mary E ^e   Massaad, Rachid ^f   McPeters, Gail ^e   Brudi, Philippe ^e   Triscari, Joseph ^e  

^a Clinical Research of South Florida   (United States)

^b Hospital CIMA San Jose   (Costa Rica)

^c UNIVERSITY OF LATVIA   (Latvia)

^d Outpatient Clinic   (Latvia)

^e MERCK RESEARCH LABORATORIES   (United States)

^f MSD Belgium   (Belgium)

Author keywords

atorvastatin; cardiovascular disease (CVD); diabetes; Ezetimibe simvastatin; rosuvastatin

Indexed keywords

ALKALINE PHOSPHATASE; APOLIPOPROTEIN B; ATORVASTATIN; C REACTIVE PROTEIN; EZETIMIBE PLUS SIMVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SIMVASTATIN;

AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLERGIC REACTION; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEPATITIS; HUMAN; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL;

AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DIABETES COMPLICATIONS; DIABETIC ANGIOPATHIES; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG MONITORING; FEMALE; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PYRIMIDINES; PYRROLES; SEVERITY OF ILLNESS INDEX; SIMVASTATIN; SULFONAMIDES;

EID: 84873435386     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164112465212     Document Type: Article

References (20)

1. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998 ; 339: 229-234 (Pubitemid 28350165)
2. Simons LA, Simons J. Diabetes and coronary heart disease. N Engl J Med. 1998 ; 339: 1714-1715
3. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003 ; 361: 2005-2016
4. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005 ; 353: 2643-2653 (Pubitemid 41817713)
5. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008 ; 31: 811-822
6. Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001 ; 285: 2486-2497
7. Catapano AL, Reiner Z, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis. 2011 ; 217: 3-46
8. Genest J, McPherson R, Frohlich J, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol. 2009 ; 25: 567-579
9. Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007 ; 28: 88-136 (Pubitemid 46137814)
10. Catapano AL, Davidson MH, Ballantyne CM, et al. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin. 2006 ; 22: 2041-2053 (Pubitemid 44663409)
11. Robinson JG, Ballantyne CM, Grundy SM, et al. Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study). Am J Cardiol. 2009 ; 103: 1694-1702
12. Goldberg RB, Guyton JR, Mazzone T, et al. Ezetimibe/ simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. Mayo Clin Proc. 2006 ; 81: 1579-1588 (Pubitemid 44871902)
13. Furman A, Meier JL, Malmstrom RA, et al. Comparative efficacy of ezetimibe/simvastatin, rosuvastatin, and atorvastatin in uncontrolled hyperlipidemia patients. Am J Manag Care. 2011 ; 17: 538-544
14. Farnier M, Averna M, Missault L, et al. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - the IN-CROSS study. Int J Clin Pract. 2009 ; 63: 547-559
15. Mark L, Paragh G, Reiber I. The role of ezetimibe in LDL cholesterol goal attainment in very high risk patients: the rosuvastatin monotherapy looks to be insufficient. Curr Med Res Opin. 2011 ; 27: 1959-1960
16. Bays HE, Davidson MH, Massaad R, et al. Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE study). Am J Cardiol. 2011 ; 108: 523-530
17. Leiter LA, Bays H, Conard S, et al. Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease. Am J Cardiol. 2008 ; 102: 1495-1501
18. Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012 ; 307: 1302-1309
19. Davidson MH, Maccubbin D, Stepanavage M, et al. Striated muscle safety of ezetimibe/simvastatin (Vytorin). Am J Cardiol. 2006 ; 97: 223-228 (Pubitemid 43139240)
20. US Food and Drug Administration. FDA Drug Safety Communication: new restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury (2011). http://www.fda.gov/Drugs/DrugSafety/ ucm256581.htm